Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study
about
sameAs
A prospective study of HDL-C and cholesteryl ester transfer protein gene mutations and the risk of coronary heart disease in the elderlyHDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathwayEvacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressureSafety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trialEvaluating and treating cardiometabolic risk factors: a case discussionAtherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statinsDescription of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of actionThe contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patientsJTT-705: is there still future for a CETP inhibitor after torcetrapib?The therapeutic role of niacin in dyslipidemia managementDrug off-target effects predicted using structural analysis in the context of a metabolic network modelHuman apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changesStructural features of cholesteryl ester transfer protein: a molecular dynamics simulation studyThe obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: II. Therapeutic management of atherogenic dyslipidemia.Screening the human serum proteome for genotype-phenotype associations: an analysis of the IL6 -174G>C polymorphism.Dalcetrapib: no off-target toxicity on blood pressure or on genes related to the renin-angiotensin-aldosterone system in ratsCholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.Homeostasis of free cholesterol in the blood: a preliminary evaluation and modeling of its passive transport.The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis?Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport.Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP).Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.Raising HDL cholesterol in women.Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database.Emerging drugs for hyperlipidemia.Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis.New lipid-modifying therapies.Seven functional polymorphisms in the CETP gene and myocardial infarction risk: a meta-analysis and meta-regressionMolecular regulation of HDL metabolism and function: implications for novel therapies.Pathophysiology of dyslipidaemia in the metabolic syndrome.Pharmacotherapy for dyslipidaemia--current therapies and future agents.Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.Alterations in high-density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins.New lipid-lowering agents.HDL revisited: new opportunities for managing dyslipoproteinaemia and cardiovascular disease.Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects.Novel HDL-directed pharmacotherapeutic strategies.Lipid-lowering therapies in development.
P2860
Q23913851-77461658-47E4-4DDD-BFB9-C8E0CB8F70B8Q24323992-99EA03EB-BC97-4D2A-A59A-207FC731A080Q24624286-6627EAAD-67AA-4532-A2BB-031E33127778Q24648125-ECAF6325-CFA1-4EBB-A0AE-BB7E23134E24Q28196750-B53DB087-F1A7-44FD-A768-0BD5AA66B49CQ28200554-3525BEC9-FB65-4F44-8705-7942FD0B50CDQ28285064-7866677F-C677-4F86-BD2E-92847F3C62FAQ28294281-8D672A81-98B9-45BE-9528-77DCA6CC35CBQ28294797-D2D8DBD2-EB89-469E-90F0-DCD3367D4864Q28304559-E2D176A0-757A-4B00-8D6E-F3D21CED4EAAQ28475693-4164C44B-8082-4000-97FA-709E3C7BA0D1Q28570515-3CB3F8E9-E203-4E5B-9FCF-F42B00FD6E3BQ30155210-9B6438FA-9D0C-418B-8A54-D9ECAE19BA20Q30380628-FDE14283-A063-4232-92D0-82AAB9256E33Q33274516-73C07760-108C-42CC-B6A7-5DA2DB88A609Q33569541-3ED09533-1ED9-4C9C-9FD2-E3DE7A0FB326Q33590777-5DD41CFA-5D23-4843-9546-1B7CA58106ABQ33639433-5A2673C1-4C6E-48A8-8AFD-4437E1957996Q33653598-511F885E-B66E-4DBC-8030-324D1B010C48Q33993233-D78FCFC0-AA70-428C-A648-6BAFE3D5E128Q34155049-90B0E296-B785-4779-BFDF-3D91720DDF25Q34220871-64ADD31C-9511-429D-9977-CEB3458F635FQ34253290-C876094A-8189-4B23-9BE6-D640C2156E4AQ34271942-C25E71A6-A0D0-4F56-86BC-9F4D3B49D7D4Q34441411-BC7EFF83-89B6-4146-B3B3-53E42718C446Q34559971-5A26BED3-020C-456C-8D2B-E869011D5736Q34619115-DE6EFB2B-54A7-4ECC-B90A-BF09D830DD33Q35034986-CA43292F-BD57-48EC-A8B9-286DEBDF532FQ35073322-9D3EF08B-4138-4BFF-8E0C-D220821F1144Q35095291-2013D2BB-7EA0-4E66-8C11-C9186B7AD5EBQ35191066-0515417F-708F-443C-B56A-B566E77B9B89Q35522107-7CBA819F-C781-4B1A-A36C-DB0596A1F8CBQ35574960-F75C8CC9-A04F-4ACF-B5F5-96B5D3729AF0Q35590298-6F60A8F9-D7EA-4FF2-92C3-6FCFA110A4F7Q35592465-BB5E78B4-3DFE-4E42-BFCB-8C7A86B3AF7BQ35602647-50834FDE-4AE4-4C5F-8C60-3C4B1BC54615Q35754375-155D4E5C-CF55-41CD-821E-DB8CE9DC72BEQ35836143-49E5AAA2-B9DC-4C01-8E13-D2ED3847D258Q35860020-0DAE20F1-916E-4F1B-B5D0-96083E5A4B67Q35925570-5FBBE139-88E2-4346-9433-E8308C862529
P2860
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Efficacy and safety of a novel ...... d phase II dose-response study
@ast
Efficacy and safety of a novel ...... d phase II dose-response study
@en
Efficacy and safety of a novel ...... d phase II dose-response study
@nl
type
label
Efficacy and safety of a novel ...... d phase II dose-response study
@ast
Efficacy and safety of a novel ...... d phase II dose-response study
@en
Efficacy and safety of a novel ...... d phase II dose-response study
@nl
prefLabel
Efficacy and safety of a novel ...... d phase II dose-response study
@ast
Efficacy and safety of a novel ...... d phase II dose-response study
@en
Efficacy and safety of a novel ...... d phase II dose-response study
@nl
P2093
P3181
P1433
P1476
Efficacy and safety of a novel ...... d phase II dose-response study
@en
P2093
Aeilko H Zwinderman
Anton F H Stalenhoef
Arie van Tol
Greetje J de Grooth
Jacqueline de Graaf
Jan Albert Kuivenhoven
Jan L Posma
John J P Kastelein
P304
P3181
P356
10.1161/01.CIR.0000015857.31889.7B
P407
P577
2002-05-07T00:00:00Z